articles

iBio’s FastPharming® Platform Produces Decoy Therapeutic to Bind to SARS-CoV-2

iBio, Inc. is developing a decoy molecule as a therapeutic against SARS-CoV-2. Recently licensed from Planet Biotechnology, the candidate is a recombinant protein made from human angiotensin ...

news

iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201

– IBIO-201 Produced Anti-Spike Neutralizing Antibodies in Pre-Clinical Studies –

events

Bioprocess International

September 21-25, 2020
Virtual

Technology

Why FastPharming ?


FastPharming overcomes issues presented by mammalian expression systems:

  • Speed: Avoids lengthy clone selection and MCB establishment processes by "transfecting at scale"
  • Scale-up: Simple & easy - just plant more plants
  • Sustainability:  Truly "green" manufacturing - no plastic waste when a plant is the "single-use bioreactor"
  • Safety:  Reduced risk of viral contamination
  • Quality:  Accessible, flexible glycosylation controls
  • Cost:  Lower facility CapEx and OpEx in many cases
Learn More

Increased Speed-to-Market


iBio CDMO Services


Process Development

FastPharming optimizes gene-expression, glycosylation, and purification parameters to deliver a robust process for your APIs.

cGMP Manufacturing

The FastPharming system transfects at large-scale to easily and reliably deliver biologics in clinical trial or commercial quantities.

Aseptic Fill/Finish

In-line labelling allows serialization of vials and bottles for greater quality assurance of mAbs, viral vectors, and other biologics.

Bioanalytics

An experienced analytical staff provides method development and validation support with expertise in protein characterization using mass spectrometry.

Factory Solutions

When the time is right, iBio facilitates insourcing by designing and building your own environmentally sustainable FastPharming facilities.

Technology Applications


The FastPharming platform produces a variety of recombinant products including:

  • Biobetter and biosimilar antibodies
  • Antigens for subunit vaccine design
  • Virus-like particles (VLP)
  • Lysosomal enzymes
  • Blood factors and cytokines
  • Scaffolds, maturogens and materials for 3D Bioprinting and biofabrication

Contact Us

Interested in applying the power of FastPharming to your project?


iBio offers the CDMO capabilities needed to develop and deliver biologics to market - process development, scale-up, cGMP manufacturing, bioanalytical product characterization, aseptic fill/finish, and quality and regulatory support.

Send us a Message